Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Lonafarnib may stop the growth of tumor cells by blocking the enzymes necessary
for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to
stop tumor cells from dividing so they stop growing or die. Giving lonafarnib together with
temozolomide may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of lonafarnib when
given together with temozolomide in treating patients with recurrent primary supratentorial
glioma.
Phase:
Phase 1
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC